Copyright
©The Author(s) 2017.
World J Gastroenterol. Jan 28, 2017; 23(4): 668-675
Published online Jan 28, 2017. doi: 10.3748/wjg.v23.i4.668
Published online Jan 28, 2017. doi: 10.3748/wjg.v23.i4.668
Figure 1 Helicobacter pylori eradication rates (full analysis set) for vonoprazan, esomeprazole, rabeprazole, and lansoprazole in first-line triple therapy.
The eradication rate was significantly higher in the VPZ group than that in the EPZ, RPZ, and LPZ groups (aP < 0.05); cP < 0.05 vs lansoprazole. VPZ 20: 20 mg VPZ, 200 mg CAM, and 750 mg AMPC twice a day for 1 wk. EPZ 20: 20 mg EPZ, 200 mg CAM, and 750 mg AMPC twice a day for 1 wk. RPZ 10: 10 mg RPZ, 200 mg CAM, and 750 mg AMPC twice a day for 1 wk. LPZ 30: 30 mg LPZ, 200 mg CAM, and 750 mg AMPC twice a day for 1 wk. VPZ: Vonoprazan; EPZ: Esomeprazole; CAM: Clarithromycin; AMPC: Amoxicillin; RPZ: Rabeprazole; LPZ: Lansoprazole; H. pylori: Helicobacter pylori.
- Citation: Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 2017; 23(4): 668-675
- URL: https://www.wjgnet.com/1007-9327/full/v23/i4/668.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i4.668